To install click the Add extension button. That's it.

The source code for the WIKI 2 extension is being checked by specialists of the Mozilla Foundation, Google, and Apple. You could also do it yourself at any point in time.

How to transfigure the Wikipedia

Would you like Wikipedia to always look as professional and up-to-date? We have created a browser extension. It will enhance any encyclopedic page you visit with the magic of the WIKI 2 technology.

Try it — you can delete it anytime.

Install in 5 seconds
4,5
Kelly Slayton
Congratulations on this excellent venture… what a great idea!
Alexander Grigorievskiy
I use WIKI 2 every day and almost forgot how the original Wikipedia looks like.
Live Statistics
English Articles
Improved in 24 Hours
Added in 24 Hours
What we do. Every page goes through several hundred of perfecting techniques; in live mode. Quite the same Wikipedia. Just better.
Great Wikipedia has got greater.
.
Leo
Newton
Brights
Milds

Rimeporide

From Wikipedia, the free encyclopedia

Rimeporide
Clinical data
ATC code
  • none
Legal status
Legal status
  • Experimental
Identifiers
  • N-(2-methyl-4,5-bis(methylsulfonyl)benzoyl)guanidine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC11H15N3O5S2
Molar mass333.38 g·mol−1
3D model (JSmol)
  • Cc1cc(c(cc1C(=O)NC(=N)N)S(=O)(=O)C)S(=O)(=O)C
  • InChI=1S/C11H15N3O5S2/c1-6-4-8(20(2,16)17)9(21(3,18)19)5-7(6)10(15)14-11(12)13/h4-5H,1-3H3,(H4,12,13,14,15)
  • Key:GROMEQPXDKRRIE-UHFFFAOYSA-N

Rimeporide is an experimental drug for the treatment of Duchenne muscular dystrophy, being developed by the EspeRare foundation.[1] it has been granted orphan drug status by the European Medicines Agency.[2]

Mechanism of action

The substance blocks an ion pump called sodium–hydrogen antiporter 1. While the exact mechanism is unknown, it is speculated that inhibition of this pump reduces pH, sodium and calcium overload in cells of patients with Duchenne muscular dystrophy.[1]

History

Rimeporide was designed as a treatment for chronic heart failure. It was tested in seven Phase I studies clinical trials in patients with congestive heart failure and some degree of renal insufficiency. Subsequently, the drug was licensed to EspeRare, a Swiss nonprofit organisation[3] that aims at repositioning drugs for rare diseases. As of May 2015, the substance has demonstrated efficacy in several animal models of Duchenne muscular dystrophy.[4]

It has also been recently tested in young boys with Duchenne muscular Dystrophy aged 6 to 11 years.[5]

See also

Other drugs for Duchenne muscular dystrophy

[6]

References

  1. ^ a b Spreitzer H (26 May 2015). "Neue Wirkstoffe – Rimeporid". Österreichische Apothekerzeitung (in German). 69 (11): 12.
  2. ^ "EspeRare's Rimeporide receives Orphan Drug Designation in Duchenne Muscular Dystrophy". EspeRare. 4 May 2015.
  3. ^ "Our mission and vision". EspeRare. Retrieved 23 July 2015.
  4. ^ Ghaleh B, Barthélemy I, Wojcik J, Sambin L, Bizé A, Hittinger L, Tran TD, Thomé FP, Blot S, Su JB (August 2020). "Protective effects of rimeporide on left ventricular function in golden retriever muscular dystrophy dogs" (PDF). International Journal of Cardiology. 312: 89–95. doi:10.1016/j.ijcard.2020.03.031. PMID 32199683. S2CID 214617920.
  5. ^ Previtali SC, Gidaro T, Díaz-Manera J, Zambon A, Carnesecchi S, Roux-Lombard P, Spitali P, Signorelli M, Szigyarto CA, Johansson C, Gray J, Labolle D, Porte Thomé F, Pitchforth J, Domingos J, Muntoni F (September 2020). "Rimeporide as a first- in-class NHE-1 inhibitor: Results of a phase Ib trial in young patients with Duchenne Muscular Dystrophy". Pharmacological Research. 159: 104999. doi:10.1016/j.phrs.2020.104999. PMC 7482441. PMID 32535224.
  6. ^ Ghaleh B, Barthélemy I, Wojcik J, Sambin L, Bizé A, Hittinger L, et al. (August 2020). "Protective effects of rimeporide on left ventricular function in golden retriever muscular dystrophy dogs" (PDF). International Journal of Cardiology. 312: 89–95. doi:10.1016/j.ijcard.2020.03.031. PMID 32199683. S2CID 214617920.
This page was last edited on 5 April 2023, at 23:33
Basis of this page is in Wikipedia. Text is available under the CC BY-SA 3.0 Unported License. Non-text media are available under their specified licenses. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc. WIKI 2 is an independent company and has no affiliation with Wikimedia Foundation.
Contact WIKI 2
Introduction
Terms of Service
Privacy Policy